(19)
(11) EP 3 271 015 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
01.11.2023 Bulletin 2023/44

(45) Mention of the grant of the patent:
27.09.2023 Bulletin 2023/39

(21) Application number: 16710199.7

(22) Date of filing: 16.03.2016
(51) International Patent Classification (IPC): 
A61P 3/04(2006.01)
A61K 31/4725(2006.01)
A61K 31/4985(2006.01)
A61K 31/472(2006.01)
A61K 31/495(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 31/472; A61K 31/4725; A61K 31/495; A61K 31/4985; A61P 3/04
(86) International application number:
PCT/EP2016/055735
(87) International publication number:
WO 2016/146712 (22.09.2016 Gazette 2016/38)

(54)

NK-3 RECEPTOR ANTAGONISTS FOR THERAPEUTIC OR COSMETIC TREATMENT OF EXCESS BODY FAT

NK-3-REZEPTORANTAGONISTEN ZUR THERAPEUTISCHEN ODER KOSMETISCHEN BEHANDLUNG VON ÜBERMÄSSIGEM KÖRPERFETT

ANTAGONISTES DES RÉCEPTEURS NK-3 POUR LE TRAITEMENT THERAPEUTIQUE OU COSMÉTIQUE DE L'EXCÈS DE GRAISSE CORPORELLE


(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 16.03.2015 EP 15159296
06.11.2015 EP 15193513

(43) Date of publication of application:
24.01.2018 Bulletin 2018/04

(73) Proprietor: OGEDA N.V.
1800 Vilvoorde (BE)

(72) Inventors:
  • HOVEYDA, Hamid
    1190 Bruxelles (BE)
  • FRASER, Graeme
    1470 Bousval (BE)

(74) Representative: Icosa 
83 avenue Denfert-Rochereau
75014 Paris
75014 Paris (FR)


(56) References cited: : 
WO-A1-2009/130240
WO-A1-2013/050424
WO-A1-2014/154896
WO-A1-2011/121137
WO-A1-2014/154895
   
  • KARAGIANNIDES ET AL: "Substance P as a Novel Anti-obesity Target", GASTROENTEROLOGY, ELSEVIER, PHILADELPHIA, PA, vol. 134, no. 3, 3 March 2008 (2008-03-03) , pages 747-755.e1, XP022516869, ISSN: 0016-5085, DOI: 10.1053/J.GASTRO.2007.12.032
  • R. RAMALHO ET AL: "Substance P antagonist improves both obesity and asthma in a mouse model", ALLERGY, vol. 68, no. 1, 26 November 2012 (2012-11-26), pages 48-54, XP055189568, ISSN: 0105-4538, DOI: 10.1111/all.12052
  • IORDANES KARAGIANNIDES ET AL: "Substance P (SP)-Neurokinin-1 Receptor (NK-1R) Alters Adipose Tissue Responses to High-Fat Diet and Insulin Action", ENDOCRINOLOGY, vol. 152, no. 6, 1 June 2011 (2011-06-01), pages 2197-2205, XP055189537, ISSN: 0013-7227, DOI: 10.1210/en.2010-1345
  • S. Y. LI ET AL: "Neurokinin B Receptor Antagonism Decreases Luteinising Hormone Pulse Frequency and Amplitude and Delays Puberty Onset in the Female Rat", JOURNAL OF NEUROENDOCRINOLOGY, vol. 26, no. 8, 22 July 2014 (2014-07-22), pages 521-527, XP055189545, ISSN: 0953-8194, DOI: 10.1111/jne.12167
  • JUDITH A SIUCIAK ET AL: "Disruption of the neurokinin-3 receptor (NK3) in mice leads to cognitive deficits", PSYCHOPHARMACOLOGY, SPRINGER, BERLIN, DE, vol. 194, no. 2, 10 June 2007 (2007-06-10) , pages 185-195, XP019537364, ISSN: 1432-2072, DOI: 10.1007/S00213-007-0828-6
  • HAMID R. HOVEYDA ET AL: "Discovery and Optimization of Novel Antagonists to the Human Neurokinin-3 Receptor for the Treatment of Sex-Hormone Disorders (Part I)", JOURNAL OF MEDICINAL CHEMISTRY, vol. 58, no. 7, 4 March 2015 (2015-03-04), pages 3060-3082, XP055187482, ISSN: 0022-2623, DOI: 10.1021/jm5017413
  • HAMID R. HOVEYDA ET AL: "Optimization of Novel Antagonists to the Neurokinin-3 Receptor for the Treatment of Sex-Hormone Disorders (Part II)", ACS MEDICINAL CHEMISTRY LETTERS, vol. 6, no. 7, 9 July 2015 (2015-07-09), pages 736-740, XP055270385, United States ISSN: 1948-5875, DOI: 10.1021/acsmedchemlett.5b00117
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).